2020
Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
Goshua G, Liu Y, Meizlish M, Fine R, Amin K, Chang E, Liu Y, McManus D, Petrosan A, Chaar C, Chun H, Defilippo N, Neuberg D, Owusu K, Lee A. Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis. Blood 2020, 136: 23-24. PMCID: PMC8330288, DOI: 10.1182/blood-2020-143349.Peer-Reviewed Original ResearchIntermediate-dose anticoagulationAnti-platelet therapyAnticoagulation cohortOverall cohortMultivariable regression modelingRothman IndexDose anticoagulationHospital deathD-dimerPropensity scoreHospitalized patientsMechanical ventilationClinical trialsCOVID-19Prophylactic-dose anticoagulationRisk-stratified algorithmUse of aspirinChronic kidney diseasePropensity-Matched AnalysisEfficacy of aspirinSeverity of illnessAnti-platelet agentsMulti-site cohortImpact of aspirinSmall vessel thrombosis
2015
Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy
Stutsky M, Reardon D, Lee A. Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy. Blood 2015, 126: 3275. DOI: 10.1182/blood.v126.23.3275.3275.Peer-Reviewed Original ResearchAnti-Xa levelsAnti-Xa monitoringLMWH doseLow molecular weight heparin therapyAbnormal body mass indexActions of providersWeight heparin therapyAcute kidney injuryChronic kidney diseaseHigh-risk patientsRetrospective chart reviewLong-term therapyBody mass indexClinical practice patternsFactor Xa inhibitorsNon-therapeutic levelsEnoxaparin doseHematology consultHeparin regimensTherapeutic LMWHHeparin therapyKidney injuryLMWH therapyRenal dysfunctionVenous thromboembolism